Parkinson's disease is a progressive neurodegenerative disorder. The classical motor
symptoms include resting tremors, bradykinesia, rigidity and postural instability and are …

Cell-replacement therapies have long been an attractive prospect for treating Parkinson
disease. However, the outcomes of fetal tissue-derived cell transplants in individuals with …

We report the implantation of patient-derived midbrain dopaminergic progenitor cells,
differentiated in vitro from autologous induced pluripotent stem cells (iPSCs), in a patient …

Cell replacement therapies for Parkinson's disease (PD) based on transplantation of
pluripotent stem cell-derived dopaminergic neurons are now entering clinical trials. Here, we …

Parkinson disease (PD) treatment options have conventionally focused on dopamine
replacement and provision of symptomatic relief. Current treatments cause undesirable …

Despite many reports of putative stem-cell-based treatments in genetic and degenerative
disorders or severe injuries, the number of proven stem cell therapies has remained small …

Parkinson disease is the second-most common neurodegenerative disorder that affects 2–
3% of the population≥ 65 years of age. Neuronal loss in the substantia nigra, which causes …

Parkinson's disease (PD) is a common neurodegenerative disease typified by a movement
disorder consisting of bradykinesia, rest tremor, rigidity, and postural instability. Treatment …

Human induced pluripotent stem cells (iPSCs) can provide a promising source of midbrain
dopaminergic (DA) neurons for cell replacement therapy for Parkinson's disease. However …

Parkinson disease (PD) is characterized by loss of the A9 nigral neurons that provide
dopaminergic innervation to the striatum. This discovery led to the successful instigation of …